FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor - FDA Press Releases

The FDA granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

from Food and Drug Administration--Press Releases https://ift.tt/2r63bdx
via IFTTT